NEW YORK (GenomeWeb News) – Atossa Genetics said today that it has signed up Millennium Healthcare to distribute its non-invasive breast cancer diagnostic test in the New York metro area and in northern New Jersey.

Under the agreement, Millennium Medical Devices will distribute and market Atossa's ForeCYTE Breast Health devices to managed-care networks, healthcare clinics, and physician practices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.